Sherbrooke Park Advisers LLC Invests $378,000 in LivaNova PLC (NASDAQ:LIVN)

Sherbrooke Park Advisers LLC bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,172 shares of the company's stock, valued at approximately $378,000.

Several other institutional investors and hedge funds have also bought and sold shares of LIVN. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC raised its stake in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after acquiring an additional 1,441 shares during the last quarter. Vestcor Inc acquired a new position in LivaNova during the 4th quarter worth about $204,000. Optimize Financial Inc acquired a new position in shares of LivaNova in the fourth quarter worth approximately $208,000. Finally, Corton Capital Inc. bought a new position in LivaNova during the 4th quarter worth approximately $214,000. Institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

LIVN traded down $0.99 during trading on Friday, reaching $42.19. The stock had a trading volume of 160,600 shares, compared to its average volume of 733,625. The business has a 50-day moving average of $38.74 and a 200-day moving average of $44.71. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock has a market cap of $2.30 billion, a PE ratio of 100.45 and a beta of 0.84.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LIVN shares. Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a report on Tuesday. Stifel Nicolaus lowered their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.